RECRUITING

PREVENT ALL ALS Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is begin funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The clinical sites are distributed across the country, and led by a group of collaborative principal investigators. Once data and samples are collected and harmonized, it will be made available to research community for future research into ALS and related neurological diseases. PREVENT protocol is specific for asymptomatic participants who are genetically at risk for ALS. The participants will be followed for up to 36 months (3 years), and will include 4 in-person on-site visits once a year and 6 off-site(remote) visits once in 4 months. The study includes collection of medical history, clinical outcomes, and blood samples once in 4 months. Additionally, the participants will complete patient reported outcomes and speech recordings once in 4 months. Participants may also provide optional Cerebrospinal Fluid (CSF) samples.The participants may also opt into a sub-study if they are interested in genetic testing for ALS causative genes. The sub-study will involve a minimum of 3 visits over a course of 2-3 months. This will include a screening/pre-test genetic counseling visit, a return of genetic results and a post-test counseling visit.

Official Title

PREVENT ALL ALS - Longitudinal Biomarker Study for Participants Who Are Genetically at Risk for Amyotrophic Lateral Sclerosis (ALS)

Quick Facts

Study Start:2024-07-25
Study Completion:2029-07-25
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06581861

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Age 18 years or older
  2. 2. Capable of providing informed consent
  3. 3. Willing to follow study procedures
  4. 4. First-degree relative of a known carrier of any ALS causative gene1 (regardless of whether ALS or FTD has actually been symptomatic in the family) OR First-degree relative of an individual with ALS and/or FTD in a family with a "compelling family history" of ALS/FTD, regardless of whether genetic testing has occurred in symptomatic family members. A "compelling family history" is defined as a pedigree with at least 2 close relatives who had ALS or FTD, with at least one of those family members having had ALS.
  5. 5. Access to a smartphone, computer, or tablet, and internet (need not be in the home - access to a public library or other available computer with internet connection is sufficient)
  1. 1. Evidence of neurological signs or symptoms concerning for ALS of FTD, at the discretion of the site investigator which will be communicated to the applicant along with referral for appropriate clinical follow-up.
  2. 2. Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, active suicidal ideation, suicide attempt, or untreated major depression \<= 90 days (about 3 months) of screening, which in the opinion of the Investigator would interfere with the study procedures
  3. 3. Clinically significant, unstable medical condition (e.g., cardiovascular instability, systemic infection, untreated thyroid dysfunction, malignant and potentially progressive cancer) that would render the participant unlikely to be able to complete 12 months of follow-up, according to Investigator's judgment
  4. 1. Medically unable to undergo lumbar puncture (LP) as determined by the site investigator (i.e., bleeding disorder, a skin infection at or near the LP site, known or suspected intracranial or intraspinal tumor or other cause of increased intracranial pressure).
  5. 2. Allergy to Lidocaine or other local anesthetic agents.
  6. 3. Use of anticoagulant medication or antiplatelet medications (aside from aspirin 81 mg) that cannot be safely withheld prior to lumbar puncture.
  7. 4. Blood dyscrasia, abnormal bleeding diathesis, or the use of dialysis for renal failure.
  8. 5. Current pregnancy based on participant self-report
  9. 6. Clinical judgement of the site investigator that the participant would be unable to undergo multiple lumbar punctures.
  10. 1. Age 18 years of age or older
  11. 2. Capable of providing informed consent
  12. 3. Willing to follow study procedures
  13. 4. Currently enrolled in the PREVENT ALS Study

Contacts and Locations

Study Contact

ALL ALS Patient Navigator
CONTACT
602-845-0248
info@all-als.org

Study Locations (Sites)

University of Alabama Birmingham
Birmingham, Alabama, 35294
United States
Barrow Neurological Institute
Phoenix, Arizona, 85013
United States
University of California San Diego
La Jolla, California, 92037
United States
University of California Irvine
Orange, California, 92868
United States
University of California, San Francisco
San Francisco, California, 94143
United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, 80045
United States
Hospital for Special Care
New Britain, Connecticut, 06053
United States
Georgetown University
Washington, District of Columbia, 200007
United States
Mayo Clinic
Jacksonville, Florida, 32224
United States
Saint Alphonsus Regional Medical Center
Boise, Idaho, 83704
United States
Northwestern University
Chicago, Illinois, 60611
United States
Indiana University
Indianapolis, Indiana, 46202
United States
John Hopkins University
Baltimore, Maryland, 21205
United States
Nih/Ninds
Bethesda, Maryland, 20892
United States
Massachusetts General Brigham
Boston, Massachusetts, 02145
United States
University of Michigan
Ann Arbor, Michigan, 48109
United States
Henry Ford Health
Detroit, Michigan, 48202
United States
University of Minnesota
Minneapolis, Minnesota, 55455
United States
Washington University
Saint Louis, Missouri, 63110
United States
University of Nebraska Medical Center
Omaha, Nebraska, 68198
United States
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756
United States
Columbia University
New York, New York, 10032
United States
Duke University
Durham, North Carolina, 27705
United States
Ohio State University
Columbus, Ohio, 43221
United States
Providence ALS Center
Portland, Oregon, 97213
United States
Penn State Health
Hershey, Pennsylvania, 17033
United States
Temple University
Philadelphia, Pennsylvania, 19140
United States
Texas Neurology
Dallas, Texas, 75206
United States
University of Utah
Salt Lake City, Utah, 84132
United States
Virginia Commonwealth University
Richmond, Virginia, 23298
United States
University of Washington
Seattle, Washington, 98195
United States

Collaborators and Investigators

Sponsor: St. Joseph's Hospital and Medical Center, Phoenix

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-07-25
Study Completion Date2029-07-25

Study Record Updates

Study Start Date2024-07-25
Study Completion Date2029-07-25

Terms related to this study

Keywords Provided by Researchers

  • ALS
  • Amyotrophic Lateral Sclerosis
  • Biomarker
  • Observational
  • at-risk

Additional Relevant MeSH Terms

  • Amyotrophic Lateral Sclerosis